Drugs / CHF6523
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04032535 | Jul 2019 → Dec 2022 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF6523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04032535 ↗ |
| Action | Inhibit | “CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)” NCT04032535 ↗ |
| Route | Inhaled | “CHF6523 is an inhaled PI3Kδ inhibitor” PMID 39427187 ↗ Oct 2024 |